文献速递艾滋病与性传播感染

HIV储存库深度分析证实多替拉韦/拉米夫定在4期随机对照转换试验(RUMBA)中的有效性与安全性

In-depth Analysis of the HIV Reservoir Confirms Effectiveness and Safety of Dolutegravir/Lamivudine in a Phase 4 Randomized Controlled Switch Trial (RUMBA).
PubMed 文献 · J Infect Dis · 2025-01-01

RUMBA是首个评估从三药方案转换为两药方案对病毒储存库影响的前瞻性随机对照试验,将病毒学抑制的受试者随机转换为多替拉韦/拉米夫定(n=89)或转换/继续比克替拉韦/恩曲他滨/丙酚替诺福韦(n=45),48周时完整HIV-1 DNA、HIV-1转录及免疫指标无显著差异,代谢结局相似。

要点

  • 转换为多替拉韦/拉米夫定与比克替拉韦/恩曲他滨/丙酚替诺福韦相比,完整HIV-1 DNA拷贝数变化无显著差异。
  • 无证据表明转换为多替拉韦/拉米夫定增加HIV-1转录活性储存库。
  • 促炎细胞因子、主要免疫细胞亚群及代谢结局两组相似。

核心结论

  • 通过深度分析完整HIV-1储存库、HIV-1转录和炎症标志物,本研究证实多替拉韦/拉米夫定相比比克替拉韦/恩曲他滨/丙酚替诺福韦具有安全性。

研究设计与样本

  • RUMBA是首个前瞻性随机对照试验,评估从三药方案转换为两药方案对病毒储存库的影响。
  • 受试者接受稳定的第二代整合酶链转移抑制剂为基础的三药方案且血浆HIV-1 RNA < 50拷贝/mL至少3个月,随机转换为多替拉韦/拉米夫定(n=89)或转换/继续比克替拉韦/恩曲他滨/丙酚替诺福韦(n=45)。
  • 48周后评估病毒学、免疫学和代谢参数。

主要发现

  • 多替拉韦/拉米夫定组与比克替拉韦/恩曲他滨/丙酚替诺福韦组相比,每百万CD4+ T细胞中完整HIV-1 DNA拷贝数的均值随时间变化无显著差异。
  • 本研究无证据表明转换为多替拉韦/拉米夫定通过HIV-1转录增加活性储存库。
  • 促炎细胞因子或主要免疫细胞亚群无显著变化。
  • 特定细胞亚群的耗竭和激活变化小且呈双向。
  • 两种治疗方案的代谢结局相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Reducing the number of active compounds for lifelong human immunodeficiency virus (HIV) treatment is of interest, especially to reduce potential long-term side effects. So far, available data assessing viral control support the robustness and safety of 2DR (2-drug regimen) antiretroviral therapy compared to 3DR. However, further in-depth investigations of the viral reservoirs are mandatory to guarantee long-term safety of these regimens regarding stable intact HIV-1 DNA copies, HIV-1 RNA transcripts, and sustained immunological control. METHODS: The RUMBA study is the first prospective randomized controlled trial evaluating the impact of switch from 3DR to 2DR on the viral reservoir. Participants on any stable second-generation integrase strand transfer inhibitor-based 3DR regimen with HIV-1 RNA < 50 copies/mL plasma for at least 3 months were randomized to switch to dolutegravir/lamivudine (DTG/3TC, n = 89) or to switch or stay on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF, n = 45). After 48 weeks, virological, immunological, and metabolic parameters were evaluated. RESULTS: We did not observe a significant difference in change over time in the mean number of intact HIV-1 DNA copies/million CD4+ T cells with DTG/3TC compared to B/F/TAF. There was no evidence in this study that switching to DTG/3TC increased the active reservoir by HIV-1 transcription. No significant changes in proinflammatory cytokines or major immune cell subsets were observed. Changes in exhaustion and activation of specific cellular subsets were small and bidirectional. Metabolic outcomes are similar between the treatment regimens. CONCLUSIONS: This study confirms the safety of DTG/3TC compared to B/F/TAF through viral control after in-depth investigations of the intact HIV-1 reservoir, HIV-1 transcription, and inflammatory markers. CLINICAL TRIALS REGISTRATION: NCT04553081.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. De Scheerder MA, Degroote S, Delporte M, et al. In-depth Analysis of the HIV Reservoir Confirms Effectiveness and Safety of Dolutegravir/Lamivudine in a Phase 4 Randomized Controlled Switch Trial (RUMBA). J Infect Dis. 2025. PMID: 39226296. doi:10.1093/infdis/jiae405

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。